Compare Aurora Cannabis Inc (ACB) vs SpaceX (SPCX) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

SPCX trades at $160.42, down 0.86% amid its Nasdaq-100 debut. Technical indicators are neutral, with support at $154 and resistance at $167. The company reported 2025 revenue of $18.67B but a net loss of $4.94B, with negative profit margins and high valuation multiples like P/S of 108.68. Recent news highlights inclusion in the Nasdaq-100 and analyst optimism, though earnings misses and cash burn from heavy investing raise concerns.

Outlook: Strong analyst consensus (100% buy, $240.80 target) reflects long-term growth faith in SpaceX's space economy role. However, persistent losses, high valuations, and execution risks in capital-intensive projects present significant downside. Investors face volatility from earnings uncertainty and competitive pressures, balancing speculative growth potential against fundamental weaknesses.